INFUSOR, FOLFUSOR, and INTERMATE Portable Elastomeric Infusion Systems 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Baxter Healthcare SA 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2013-10-02
  • 사례 출판 날짜
    2013-10-02
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: baxter infusor, folfusor, and intermate portable elastomeric infusion systems the medicines and healthcare products regulatory agency (mhra), united kingdom (uk) posted a medical device safety alert concerning infusor, folfusor, and intermate portable elastomeric infusion systems manufactured by baxter healthcare sa. all lots are affected. baxter has received complaints for infusion flow rates greater than intended for the above portable elastomeric infusion systems. in many cases, the complaint details an overinfusion of medication that is the result of uses inconsistent with the instructions for use (ifu). as delivery of medication at an infusion rate faster than intended may lead to toxicity or changes to efficacy that require medical attention, baxter is requesting that healthcare providers continue to follow the device ifu which explains the following factors that may impact resulting flow rate: the choice of medication: refer to the drug manufacturer’s package insert for drug reconstitution/dilution and storage procedures. instructions for calculating the correct fill volumes including the potential for increase in flow rate which may result from a fill volume below the stated nominal fill volume. temperature change on the device. choice of the diluents (5% dextrose vs. 0.9% sodium chloride) as a ~10% increase in nominal flow rate may result when 0.9% sodium chloride is used. the position of the elastomeric reservoir in relation to the distal end luer lock. flow rate will decrease ~0.5% for every inch the elastomeric reservoir is positioned below the distal end luer lock and increase ~0.5% for every inch the elastomeric reservoir is positioned above the distal end luer lock. length, diameter, and location of catheter. for details, please visit the following mhra website: http://www.Mhra.Gov.Uk/safetyinformation/safetywarningsalertsandrecalls/fieldsafetynotices/con316301 according to the local supplier, the affected products were distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 2 october 2013.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Baxter INFUSOR, FOLFUSOR, and INTERMATE Portable Elastomeric Infusion Systems
  • Manufacturer

Manufacturer